Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
Go back to Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)| (NASDAQ: IONS) | Delayed: 75.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.99 | 52 Week High | $62.68 | |||
| Open | $75.99 | 52 Week Low | $19.59 | |||
| Day High | $75.99 | P/E | N/A | |||
| Day Low | $75.99 | EPS | $0.00 | |||
| Volume | 39 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 38,249 | |||||
